Loading...
XHKG3737
Market cap105mUSD
Dec 30, Last price  
0.97HKD
1D
-2.02%
1Q
-3.96%
Jan 2017
-40.49%
IPO
-60.73%
Name

Zhongzhi Pharmaceutical Holdings Ltd

Chart & Performance

D1W1MN
XHKG:3737 chart
P/E
4.74
P/S
0.38
EPS
0.19
Div Yield, %
14.17%
Shrs. gr., 5y
0.33%
Rev. gr., 5y
12.41%
Revenues
2.05b
+12.26%
482,805,000595,565,000688,036,000730,472,000944,634,0001,142,150,0001,342,182,0001,603,876,0001,746,500,0001,825,935,0002,049,812,000
Net income
163m
+53.00%
37,638,00086,688,00080,539,00053,872,00070,056,00085,069,000114,694,000138,532,00052,128,000106,387,000162,775,000
CFO
102m
-64.33%
44,983,000121,637,00056,040,00049,035,00051,183,00079,824,000167,827,00093,179,000178,379,000284,574,000101,503,000
Dividend
May 24, 20240.032319 HKD/sh
Earnings
May 16, 2025

Profile

Zhongzhi Pharmaceutical Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company operates through three segments: Pharmaceutical Manufacturing, Operation of Chain Pharmacies, and Operation of On-Line Pharmacies. It provides Chinese patent medicines and decoction pieces under the Zeus, Liumian, and Caojinghua brands. The company is also manufacture and sale of food and Chinese herbs; property management; and pharmaceutical drugs, as well as offers detection and testing services. As of December 31, 2021, it operated 398 self-operated chain pharmacies, including 361 medical insurance designated pharmacies located in Zhongshan in the Guangdong Province under the Zeus brand. The company was founded in 1993 and is headquartered in Zhongshan, the People's Republic of China. Zhongzhi Pharmaceutical Holdings Limited is a subsidiary of Crystal Talent Investment Group Limited.
URL
http://www.zeus.cn/
IPO date
Jul 13, 2015
Employees
2,834
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,049,812
12.26%
1,825,935
4.55%
Cost of revenue
1,876,458
1,718,766
Unusual Expense (Income)
NOPBT
173,354
107,169
NOPBT Margin
8.46%
5.87%
Operating Taxes
43,447
23,736
Tax Rate
25.06%
22.15%
NOPAT
129,907
83,433
Net income
162,775
53.00%
106,387
104.09%
Dividends
(116,145)
(230)
Dividend yield
9.66%
0.02%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
75,582
76,239
Long-term debt
224,120
229,450
Deferred revenue
11,866
15,842
Other long-term liabilities
Net debt
58,084
(107,922)
Cash flow
Cash from operating activities
101,503
284,574
CAPEX
(169,178)
(88,407)
Cash from investing activities
(202,758)
13,380
Cash from financing activities
(154,618)
(68,144)
FCF
(103,717)
204,916
Balance
Cash
192,304
395,697
Long term investments
49,314
17,914
Excess cash
139,127
322,314
Stockholders' equity
1,077,350
803,078
Invested Capital
1,100,929
805,640
ROIC
13.63%
10.03%
ROCE
13.76%
9.27%
EV
Common stock shares outstanding
846,998
846,998
Price
1.42
30.28%
1.09
10.10%
Market cap
1,202,738
30.28%
923,228
11.42%
EV
1,376,382
818,279
EBITDA
275,433
200,753
EV/EBITDA
5.00
4.08
Interest
7,868
6,555
Interest/NOPBT
4.54%
6.12%